Regeneron Pharma stock (US75886F1075): U.S. shares trade around USD 593 after recent pipeline and ownership updates

Regeneron Pharma shares on Nasdaq traded around USD 593 in early June 2026 as investors digest late-May pipeline news and fresh institutional ownership disclosures in the United States.

Regeneron Pharma shares on the Nasdaq Global Select Market recently changed hands at about USD 593, leaving the U.S.-listed biotech group with a market capitalization of roughly USD 62.2 billion as of 06/01/2026, according to Robinhood price data as of 06/01/2026.Robinhood as of 06/01/2026

The stock, which trades under the ticker REGN in the United States, recorded an intraday high of USD 599.90 and a low of USD 599.90 in the session referenced by Robinhood, illustrating relatively tight trading on that day even as the broader biotech sector remained sensitive to trial and regulatory headlines.Robinhood as of 06/01/2026

As of: 02.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Regeneron
• Sector/industry: Biotechnology and pharmaceuticals
• Headquarters/country: Tarrytown, United States
• Core markets: United States, Europe and other international markets
• Key revenue drivers: Specialty biologics in ophthalmology, immunology and rare diseases
• Home exchange/listing venue: Nasdaq Global Select Market (REGN)
• Trading currency: USD

Regeneron Pharma: core business model

Regeneron focuses on discovering and developing monoclonal antibody-based medicines and other biologics, with sales concentrated in high-value therapeutic areas such as eye disease, inflammatory conditions and selected rare disorders.

Latest quarterly results for Regeneron Pharma at a glance

On 05/02/2024, Regeneron reported its first-quarter 2024 results, providing the latest full quarterly snapshot that investors in the United States continue to reference while trading the stock in 2026, according to the company’s earnings release as of 05/02/2024.Regeneron investor relations as of 05/02/2024

In that period, the company highlighted revenue contributions from its key biologic franchises, underscoring the importance of U.S. demand and international expansion in Europe and other markets, while also reaffirming its strategic focus on pipeline assets that could support longer-term growth beyond the current product portfolio.Regeneron investor relations as of 05/02/2024

Conclusion

Regeneron Pharma’s recent trading around USD 593 on the Nasdaq Global Select Market keeps the United States firmly at the center of the investment story, with valuation still anchored in expectations for its existing biologics portfolio and late-stage pipeline.

The latest available quarterly figures from 2024 continue to provide a reference point for how U.S. and international sales are developing, while investors monitor new data readouts, regulatory decisions and institutional flows for clues about how the revenue mix and growth profile could evolve.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.